Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Scientific Officer | December 20, 2023 | December 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zentalis Pharmaceuticals, Inc.
Report date December 20, 2023 · Filed December 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 834,931 |
Reported balance
After 2023-12-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-20 · Gift · Disposed 24,158 · Balance 834,931 F1: The Reporting Person transferred 24,158 shares to the Raising Hope Foundation, a charitable foundation of which the Reporting Person is a director. The Reporting Person has voting and investment power over all securities owned by the Raising Hope Foundation. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 15,000 |
Reported balance
Holding disclosure · report date 2023-12-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,000 F2: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectAs UTMA custodian for sons | 350 |
Reported balance
Holding disclosure · report date 2023-12-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 350 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person transferred 24,158 shares to the Raising Hope Foundation, a charitable foundation of which the Reporting Person is a director. The Reporting Person has voting and investment power over all securities owned by the Raising Hope Foundation.
F2: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2021 Filed Dec 13, 2021 18:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,117 | $72.10 | $368,950.54 |
DisclosureSEC source: 0001725160-21-000238 · wf-form4_163943697239815.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 210,400 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $71.75 to $72.59. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 18:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,049 | $71.17 | $288,150.73 |
DisclosureSEC source: 0001725160-21-000238 · wf-form4_163943697239815.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 215,517 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $70.74 to $71.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 18:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 434 | $70.29 | $30,504.99 |
DisclosureSEC source: 0001725160-21-000238 · wf-form4_163943697239815.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 219,566 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $69.70 to $70.66. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 16:45 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 10,000 | $75.99 | $759,937.00 |
DisclosureSEC source: 0001725160-21-000228 · wf-form4_163770390481652.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 220,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 16:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 10,000 | $78.15 | $781,471.00 |
DisclosureSEC source: 0001725160-21-000222 · wf-form4_163675307845064.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 230,000 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F1 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 16:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000222 · wf-form4_163675307845064.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 240,000 F1 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 16:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000222 · wf-form4_163675307845064.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,067 Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 21:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 204 | $67.44 | $13,758.76 |
DisclosureSEC source: 0001725160-21-000200 · wf-form4_163339659793245.xml · nonDerivative · entry 6 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F8 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $67.44 to $67.45. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 21:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,679 | $66.89 | $246,075.43 |
DisclosureSEC source: 0001725160-21-000200 · wf-form4_163339659793245.xml · nonDerivative · entry 5 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 204 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.41 to $67.34. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 21:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,121 | $65.80 | $205,362.42 |
DisclosureSEC source: 0001725160-21-000200 · wf-form4_163339659793245.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,883 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $65.29 to $66.27. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 21:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,416 | $64.73 | $91,658.95 |
DisclosureSEC source: 0001725160-21-000200 · wf-form4_163339659793245.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,004 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $64.26 to $65.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 24, 2021 Filed Oct 4, 2021 21:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000200 · wf-form4_163339659793245.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · As UTMA custodian for sons Disclosed balance after: 350 F1 · kind: Transfer to Reporting Person in his capacity as custodian for sons under Uniform Transfers to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 24, 2021 Filed Oct 4, 2021 21:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000200 · wf-form4_163339659793245.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,067 F1 · kind: Transfer to Reporting Person in his capacity as custodian for sons under Uniform Transfers to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any. F2 · balance_after: Includes 576 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2021. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 19:31 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 400 | $68.58 | $27,432.00 |
DisclosureSEC source: 0001725160-21-000189 · wf-form4_163062549627527.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,420 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $68.57 to $68.59. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 19:31 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,198 | $67.77 | $284,488.80 |
DisclosureSEC source: 0001725160-21-000189 · wf-form4_163062549627527.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,820 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $67.45 to $68.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 19:31 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,822 | $67.08 | $256,362.18 |
DisclosureSEC source: 0001725160-21-000189 · wf-form4_163062549627527.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,018 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.45 to $67.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 19:59 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 307 | $53.32 | $16,368.26 |
DisclosureSEC source: 0001725160-21-000175 · wf-form4_162803516879962.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 16,840 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.02 to $53.49. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 19:59 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,246 | $52.41 | $65,299.62 |
DisclosureSEC source: 0001725160-21-000175 · wf-form4_162803516879962.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 17,147 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.92 to $52.86. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 19:59 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,728 | $51.35 | $191,430.94 |
DisclosureSEC source: 0001725160-21-000175 · wf-form4_162803516879962.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 18,393 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.92 to $51.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 19:59 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,139 | $49.92 | $156,706.10 |
DisclosureSEC source: 0001725160-21-000175 · wf-form4_162803516879962.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,121 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.57 to $50.27. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 16:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,506 | $47.76 | $71,930.48 |
DisclosureSEC source: 0001725160-21-000168 · wf-form4_162577771080641.xml · nonDerivative · entry 6 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,788 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.56 to $48.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 16:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,842 | $47.28 | $87,089.94 |
DisclosureSEC source: 0001725160-21-000168 · wf-form4_162577771080641.xml · nonDerivative · entry 5 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,294 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.55 to $47.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 16:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,166 | $46.08 | $53,727.41 |
DisclosureSEC source: 0001725160-21-000168 · wf-form4_162577771080641.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,136 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.52 to $46.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 16:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 200 | $49.21 | $9,841.00 |
DisclosureSEC source: 0001725160-21-000168 · wf-form4_162577771080641.xml · nonDerivative · entry 9 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 994,841 F8 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F11 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.96 to $49.45. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 16:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 800 | $47.33 | $37,863.84 |
DisclosureSEC source: 0001725160-21-000168 · wf-form4_162577771080641.xml · nonDerivative · entry 8 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,041 F8 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F10 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.24 to $47.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 16:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 12,947 | $46.84 | $606,390.87 |
DisclosureSEC source: 0001725160-21-000168 · wf-form4_162577771080641.xml · nonDerivative · entry 7 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,841 F8 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.23 to $47.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 16:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 96 | $48.83 | $4,688.07 |
DisclosureSEC source: 0001725160-21-000168 · wf-form4_162577771080641.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013,302 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.11 to $49.01. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 16:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,349 | $47.17 | $63,628.01 |
DisclosureSEC source: 0001725160-21-000168 · wf-form4_162577771080641.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013,398 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.08 to $48.07. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 16:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,906 | $46.78 | $229,515.44 |
DisclosureSEC source: 0001725160-21-000168 · wf-form4_162577771080641.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014,747 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.08 to $47.06. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 420 | $53.18 | $22,336.02 |
DisclosureSEC source: 0001725160-21-000164 · wf-form4_162561607250180.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 25,260 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $53.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,473 | $52.18 | $76,858.05 |
DisclosureSEC source: 0001725160-21-000164 · wf-form4_162561607250180.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 25,680 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.89 to $52.84. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,127 | $51.30 | $211,732.85 |
DisclosureSEC source: 0001725160-21-000164 · wf-form4_162561607250180.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 27,153 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.87 to $51.86. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,400 | $50.18 | $120,439.92 |
DisclosureSEC source: 0001725160-21-000164 · wf-form4_162561607250180.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,280 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.81 to $50.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:26 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 849 | $54.86 | $46,574.44 |
DisclosureSEC source: 0001725160-21-000136 · wf-form4_162267998190811.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 33,680 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.59 to $55.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:26 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 7,571 | $54.00 | $408,867.31 |
DisclosureSEC source: 0001725160-21-000136 · wf-form4_162267998190811.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 34,529 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.54 to $54.47. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 5, 2021 16:28 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,123 | $60.23 | $67,638.85 |
DisclosureSEC source: 0001725160-21-000122 · wf-form4_162024647690443.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 42,100 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.15 to $60.45. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 03, 2021 Filed May 5, 2021 16:28 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,567 | $59.91 | $273,629.98 |
DisclosureSEC source: 0001725160-21-000122 · wf-form4_162024647690443.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 43,223 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $59.15 to $60.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 03, 2021 Filed May 5, 2021 16:28 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,630 | $58.09 | $94,678.71 |
DisclosureSEC source: 0001725160-21-000122 · wf-form4_162024647690443.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,790 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $57.74 to $58.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 03, 2021 Filed May 5, 2021 16:28 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,100 | $57.12 | $62,836.29 |
DisclosureSEC source: 0001725160-21-000122 · wf-form4_162024647690443.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 49,420 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $56.56 to $57.55. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 17:06 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,810 | $45.00 | $171,450.00 |
DisclosureSEC source: 0001725160-21-000094 · wf-form4_161843439429418.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 50,520 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 06, 2021 Filed Apr 6, 2021 17:43 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 275 | $43.26 | $11,897.00 |
DisclosureSEC source: 0001725160-21-000089 · wf-form4_161774532038498.xml · nonDerivative · entry 5 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019,653 F5 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 17:43 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 400 | $45.07 | $18,027.52 |
DisclosureSEC source: 0001725160-21-000089 · wf-form4_161774532038498.xml · nonDerivative · entry 6 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 54,330 F5 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.00 to $45.11. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 17:43 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 15,361 | $43.36 | $666,052.96 |
DisclosureSEC source: 0001725160-21-000089 · wf-form4_161774532038498.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019,928 F5 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 17:43 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 54 | $45.06 | $2,433.27 |
DisclosureSEC source: 0001725160-21-000089 · wf-form4_161774532038498.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035,289 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $44.87 to $45.11. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 17:43 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 97 | $44.21 | $4,288.84 |
DisclosureSEC source: 0001725160-21-000089 · wf-form4_161774532038498.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035,343 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $43.87 to $44.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 17:43 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,024 | $43.37 | $391,332.08 |
DisclosureSEC source: 0001725160-21-000089 · wf-form4_161774532038498.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035,440 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $42.87 to $43.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 19:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 100 | $44.90 | $4,490.00 |
DisclosureSEC source: 0001725160-21-000078 · wf-form4_161766647984112.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 54,730 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 19:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,674 | $43.88 | $73,448.59 |
DisclosureSEC source: 0001725160-21-000078 · wf-form4_161766647984112.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 54,830 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $43.52 to $44.45. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 19:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,436 | $43.09 | $104,977.96 |
DisclosureSEC source: 0001725160-21-000078 · wf-form4_161766647984112.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 56,504 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $42.51 to $43.49. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 10, 2021 Filed Mar 10, 2021 20:26 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,720 | $45.24 | $213,542.24 |
DisclosureSEC source: 0001725160-21-000057 · wf-form4_161542600145358.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 58,940 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.06 to $45.49. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.